ISSN: 2329-8790
+44 1478 350008
Momot AP, Nikolaeva MG and Zainulina MS
The article defines the role of a combination of several acquired thrombogenic risk factors with Activated Protein C (APC) resistance which is due to carriage of FVL (1691)GA genotype to develop Venous Thromboembolic Complications (VTEC). In this regard, a prospective clinical study of 1100 women of reproductive age was conducted. The patients were divided into two groups. The main group–500 patients with FVL (1691)GA genotype, and the control group–600 women with FVL(1691)GG genotype. Based on the findings of the conducted study, it was concluded that carriage of FVL (1691)GA genotype is associated with VTEC development compared to the normozygous genotype. The highest incidence of primary thrombotic events was identified on the background of combined hormonal contraceptive administration. In the event of VTEC, carriers of Factor V Leiden (FVL (1691)GA) mutation often suffer from hypertensive disorders, varicose disease of the lower extremities, overweight and/or combinations of these pathology types. It was defined that in all cases of thrombosis episode, the value of APC resistance was ≤ 0.49 according to Normalized Ratio (NR), while episodes of VTEC were not observed in NR ≥ 0.5.